lanifibranors

Lanifibranor is an investigational drug being developed for the treatment of nonalcoholic steatohepatitis (NASH), a chronic liver disease characterized by inflammation and liver cell damage. It belongs to a class of compounds known as pan-PPAR agonists, meaning it activates multiple peroxisome proliferator-activated receptor (PPAR) subtypes. These receptors play a role in regulating metabolism, inflammation, and fibrosis in the liver.

By activating PPAR alpha, gamma, and delta, lanifibranor aims to address the multifaceted nature of NASH. Activation of PPAR alpha is thought to reduce lipid accumulation and inflammation, while PPAR gamma activation can improve insulin sensitivity and reduce inflammation. PPAR delta activation may contribute to enhanced fatty acid oxidation and reduced inflammation.

Clinical trials have evaluated lanifibranor's efficacy and safety in patients with biopsy-proven NASH. Studies have aimed to assess its impact on liver histology, including improvements in steatosis (fatty liver), inflammation, ballooning degeneration, and fibrosis. The drug is administered orally. Research continues to explore its potential as a therapeutic option for NASH, a condition with significant unmet medical needs.